Last updated: July 23, 2026
Executive summary: Forest Laboratories, LLC sued Aurobindo Pharma Ltd. in the U.S. District Court for the District of Delaware under Hatch-Waxman (Paragraph IV) in case number 1:17-cv-01210. The dispute centers on Aurobindo’s planned generic entry for an NDA owned or controlled by Forest. The litigation posture (claims asserted, patents at issue, and whether the case ended in a consent judgment, stipulation, or trial verdict) determines the regulatory launch timing risk and the practical scope of any settlement-based “carve-out” to design-arounds. Without the docket’s patent list and disposition details, a complete, case-specific merits analysis cannot be produced.
What patents were asserted in Forest Laboratories, LLC v. Aurobindo Pharma Ltd. 1:17-cv-01210?
Featured snippet answer: The specific patents asserted in 1:17-cv-01210 must be identified from the complaint and any later amended pleadings. Those document-level inputs determine the asserted expiration dates, claim categories (composition, formulation, method-of-use, polymorph, or manufacturing), and the infringement theory (ANDA contents and label carve-outs).
Which patent numbers and claim types typically appear in Paragraph IV filings for Forest portfolio cases?
Forest’s Paragraph IV litigations in CNS and related therapeutic areas commonly involve:
- Composition-of-matter claims on the active pharmaceutical ingredient
- Formulation claims on dosage forms, film coating, solvation, or release characteristics
- Method-of-use claims that map to the FDA label and indication section
- Manufacturing/process claims where ANDA processes are used as infringement predicates
This case-specific breakdown requires the docket’s “patents-in-suit” listing.
How to map the patents-in-suit to exclusivity and generic timing
Once patents-in-suit are known, the analysis typically produces:
- Earliest patent expiration
- Latest PTE/PTE-like adjustments (if any) impacting real expiry
- Any listed Orange Book exclusivity codes tied to approval
- Whether the case includes use-code alignment that changes launch eligibility
What did Aurobindo challenge in its ANDA and what FDA pathway was involved?
Featured snippet answer: ANDA specifics (reference listed drug, submission paragraph IV patents, and whether it included generic-only or authorized product carve-outs) drive the infringement and invalidity case framing. Those facts are set in the ANDA certification and the complaint’s “detailed statement.”
What does the “Paragraph IV” certification determine in the litigation?
The certification mechanics determine:
- Which patents are alleged to be invalid and/or not infringed
- Whether the generic label includes “carve-outs” (section-by-section indication exclusions)
- Whether statutory launch at risk could be blocked by a case stay under 21 U.S.C. § 355(j)(5)(B)
How label carve-outs affect design-around and noninfringement
If Aurobindo’s proposed labeling excludes specific indications or claim-relevant language, noninfringement theories often turn on:
- Therapeutic indication scope in the proposed label
- Dosing regimen statements tied to method-of-use claims
- Whether the claim limitation appears in the proposed instruction manual
When did the litigation start and what procedural milestones controlled the exclusivity clock?
Featured snippet answer: The key date inputs are the complaint filing date and the timing under Hatch-Waxman’s 30-month stay framework. Those determine whether the case started early enough to block final FDA approval and initial marketing.
Timing elements used in Hatch-Waxman timelines
A case timeline typically tracks:
- Complaint filing date in federal court
- Service and notice to FDA
- Any amended pleadings re: additional patents-in-suit
- Entry of case schedule, claim construction (if any)
- Settlement date or dispositive motion date
A docket-level chronology is required for precision.
How strong was the patent estate in this dispute, based on typical infringement and invalidity patterns?
Featured snippet answer: Strength cannot be assessed without the patents-in-suit, their remaining life, the court’s rulings on claim construction and dispositive motions, and the infringement theory.
Court outcomes that shift the risk profile
Patent estate strength is usually measured by:
- Survival of asserted claims at motion to dismiss / summary judgment stages
- Claim construction outcomes that narrow or broaden claim scope
- Obviousness anticipation patterns based on cited prior art
- Enablement and written description challenges
What “invalidity levers” dominate Paragraph IV cases involving Forest portfolios
Without patent numbers, the general high-probability levers are:
- Anticipation by earlier published applications or patents
- Obviousness combining the active ingredient with known formulations or dosing
- Lack of enablement for process or polymorph-specific claims
- Indefiniteness for functional limitations
Case-specific invalidity grounds must be pulled from the responsive pleadings and claim charts.
What was the settlement posture and did the case end with a consent judgment or dismissal?
Featured snippet answer: The practical launch impact depends on whether the parties settled before judgment and whether the settlement imposed market-entry dates, exclusivity carve-outs, or non-working covenants.
How settlement terms usually show up in Hatch-Waxman cases
Settlement documentation often includes:
- Stipulation of dismissal with prejudice or without prejudice
- Agreement on a stipulated launch date
- Mutual covenants not to sue within defined design parameters
- License scope for patented formulations or uses, if negotiated
The exact settlement instrument and its terms must be confirmed from the docket.
Did Forest Laboratories receive a court ruling that blocked Aurobindo’s entry?
Featured snippet answer: A “block” occurs if the court granted permanent injunction after a merits finding, entered summary judgment of infringement/validity, or issued rulings that effectively precluded a design-around while the case was pending.
Merits judgment vs. procedural resolution
Resolution categories with different business consequences:
- Merits infringement/validity rulings: strong downstream leverage, higher enforcement value
- Procedural dismissal/settlement: often yields predictable launch terms but may reduce future litigation leverage
- Summary judgment invalidity: drives faster generic approvals for same-world design and labels
This must be tied to the actual dispositive entries for 1:17-cv-01210.
What is the Orange Book status of the reference listed drug implicated in this case?
Featured snippet answer: Orange Book status requires identifying the RLD and then listing:
- Patent numbers tied to the NDA
- Expiration dates
- Exclusivity periods that are not patent-based (including data exclusivity and pediatric exclusivity)
- Whether the patents-in-suit cover the NDA’s active ingredient vs. adjunct claims
Because the RLD identity is not included in the prompt, an accurate Orange Book mapping cannot be produced.
Which generic entry risks existed for Aurobindo based on the litigation outcome?
Featured snippet answer: Generic entry risk depends on:
- Remaining enforceable patents (post-dismissal or post-settlement)
- Whether Aurobindo is required to maintain label carve-outs
- Whether a design-around is sufficient to avoid infringement
- Whether any additional “follow-on” patents in the Orange Book could be asserted later
A risk matrix needs the asserted patents and the disposition.
How does this case compare with other Forest v. generic disputes in the same therapeutic space?
Featured snippet answer: Comparative analysis requires a database of:
- Similar defendants (other ANDA filers)
- Similar asserted patent families
- Common procedural patterns (early settlement vs. claim construction then settlement)
- Typical settlement structure (launch date, indemnity, exclusivity carve-outs)
No comparable case list can be completed from the prompt.
Key litigation takeaways for licensing, enforcement, and R&D planning
Featured snippet answer: Business actions depend on whether 1:17-cv-01210 resulted in (i) a binding final merits finding on patent validity/infringement, or (ii) a settlement that defines market-entry constraints.
In general, the decision tree is:
- If patents-in-suit were upheld: higher likelihood of injunction leverage in enforcement and follow-on suits.
- If invalidity was upheld or claims were narrowed: lower enforcement probability, higher generic launch probability.
- If settlement fixed a launch date: track the date and design-around conditions as the controlling constraints for product launch and label.
Key Takeaways
- 1:17-cv-01210 is a Hatch-Waxman-style dispute between Forest Laboratories, LLC and Aurobindo Pharma Ltd.
- The practical impact for launch timing and enforcement hinges on the patents-in-suit and the disposition (merits ruling vs. settlement vs. dismissal).
- A defensible, patent-by-patent and timeline-specific analysis cannot be completed from the provided input because the docket’s complaint contents and final orders are not included.
FAQs
- What is the meaning of a Paragraph IV certification in Forest v. Aurobindo cases?
- How do settlement terms in Hatch-Waxman cases affect FDA labeling carve-outs?
- What happens to 30-month stay timing if a case is dismissed early?
- How are method-of-use patents evaluated against proposed generic labeling?
- How do Orange Book patent listings interact with later enforcement of “follow-on” patents?
References
No sources cited because no docket documents, complaint details, court orders, Orange Book RLD identification, or patent lists were provided in the prompt.
